TY - JOUR
T1 - Atypical Presentation of Pregnancy-Related Hemolytic Uremic Syndrome
AU - Baghli, Salim
AU - Abendroth, Catherine
AU - Farooq, Umar
AU - Schaub, Jennifer A.
N1 - Publisher Copyright:
© 2017 National Kidney Foundation, Inc.
PY - 2018/9
Y1 - 2018/9
N2 - The cause of acute kidney injury during pregnancy and in the postpartum period can be particularly challenging to diagnose, especially when it is necessary to differentiate among preeclampsia; eclampsia; hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome; and thrombotic microangiopathies (TMAs). All these disease entities can present with kidney failure, microangiopathic hemolytic anemia, and thrombocytopenia. We present a teaching case of atypical hemolytic uremic syndrome in the postpartum period in a young woman who was found to have mutations of uncertain clinical significance in the complement cascade, including in C3, CFH, and CFI. We use this as an opportunity to review the clinical presentation and pathophysiology of preeclampsia, eclampsia, and the TMAs. We focus on diagnostic challenges, especially because many patients with TMA do not present with thrombocytopenia, which can delay diagnosis. We additionally review the clinical settings in which administration of eculizumab, a C5 membrane attack complex inhibitor, is appropriate.
AB - The cause of acute kidney injury during pregnancy and in the postpartum period can be particularly challenging to diagnose, especially when it is necessary to differentiate among preeclampsia; eclampsia; hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome; and thrombotic microangiopathies (TMAs). All these disease entities can present with kidney failure, microangiopathic hemolytic anemia, and thrombocytopenia. We present a teaching case of atypical hemolytic uremic syndrome in the postpartum period in a young woman who was found to have mutations of uncertain clinical significance in the complement cascade, including in C3, CFH, and CFI. We use this as an opportunity to review the clinical presentation and pathophysiology of preeclampsia, eclampsia, and the TMAs. We focus on diagnostic challenges, especially because many patients with TMA do not present with thrombocytopenia, which can delay diagnosis. We additionally review the clinical settings in which administration of eculizumab, a C5 membrane attack complex inhibitor, is appropriate.
UR - http://www.scopus.com/inward/record.url?scp=85040227532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040227532&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2017.11.006
DO - 10.1053/j.ajkd.2017.11.006
M3 - Article
C2 - 29331477
AN - SCOPUS:85040227532
SN - 0272-6386
VL - 72
SP - 451
EP - 456
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3
ER -